Raptor Pharmaceutical Corp. (RPTP) Receives Hold Rating from FBR & Co
Raptor Pharmaceutical Corp. (NASDAQ:RPTP)‘s stock had its “hold” rating reissued by FBR & Co in a note issued to investors on Thursday.
Several other equities analysts have also recently issued reports on the stock. Cowen and Company restated a “buy” rating and issued a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Friday, August 19th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Thursday, August 11th. Finally, Citigroup Inc. cut shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their price target for the company from $6.00 to $8.00 in a research report on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Raptor Pharmaceutical Corp. currently has an average rating of “Hold” and a consensus target price of $7.79.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down 2.23% during midday trading on Thursday, reaching $7.45. 752,596 shares of the company traded hands. Raptor Pharmaceutical Corp. has a 12-month low of $2.94 and a 12-month high of $9.06. The company has a 50 day moving average of $6.82 and a 200-day moving average of $5.42. The stock’s market capitalization is $635.53 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/raptor-pharmaceutical-corp-rptp-receives-hold-rating-from-fbr-co.html
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The business earned $32.05 million during the quarter, compared to analysts’ expectations of $28.52 million. Raptor Pharmaceutical Corp. had a negative net margin of 79.29% and a negative return on equity of 66.67%. The firm’s quarterly revenue was up 37.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) EPS. Equities analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.91) EPS for the current fiscal year.
A number of hedge funds and institutional investors recently modified their holdings of the company. Jacobs Levy Equity Management Inc. bought a new position in shares of Raptor Pharmaceutical Corp. during the first quarter valued at about $771,000. Quantitative Systematic Strategies LLC bought a new position in shares of Raptor Pharmaceutical Corp. during the second quarter valued at about $495,000. Renaissance Technologies LLC raised its position in shares of Raptor Pharmaceutical Corp. by 7.5% in the first quarter. Renaissance Technologies LLC now owns 572,946 shares of the company’s stock valued at $2,636,000 after buying an additional 40,066 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Raptor Pharmaceutical Corp. by 7.0% in the first quarter. Geode Capital Management LLC now owns 573,082 shares of the company’s stock valued at $2,636,000 after buying an additional 37,740 shares in the last quarter. Finally, Squarepoint Ops LLC raised its position in shares of Raptor Pharmaceutical Corp. by 45.0% in the first quarter. Squarepoint Ops LLC now owns 65,400 shares of the company’s stock valued at $301,000 after buying an additional 20,300 shares in the last quarter. 55.07% of the stock is currently owned by institutional investors and hedge funds.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.
Receive News & Ratings for Raptor Pharmaceutical Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Raptor Pharmaceutical Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.